Catalina Capital Group LLC Purchases 1,473 Shares of Johnson & Johnson (NYSE:JNJ)

Catalina Capital Group LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 22.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,098 shares of the company’s stock after buying an additional 1,473 shares during the quarter. Catalina Capital Group LLC’s holdings in Johnson & Johnson were worth $1,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of JNJ. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $765,000. Almanack Investment Partners LLC. increased its stake in Johnson & Johnson by 1.3% in the 1st quarter. Almanack Investment Partners LLC. now owns 6,430 shares of the company’s stock worth $1,017,000 after purchasing an additional 80 shares during the period. Lincoln National Corp increased its stake in Johnson & Johnson by 1.4% in the 1st quarter. Lincoln National Corp now owns 77,322 shares of the company’s stock worth $12,231,000 after purchasing an additional 1,083 shares during the period. Hendley & Co. Inc. increased its stake in shares of Johnson & Johnson by 0.3% during the first quarter. Hendley & Co. Inc. now owns 63,461 shares of the company’s stock valued at $10,039,000 after buying an additional 214 shares during the period. Finally, Horan Securities Inc. increased its stake in shares of Johnson & Johnson by 30.9% during the first quarter. Horan Securities Inc. now owns 6,483 shares of the company’s stock valued at $1,026,000 after buying an additional 1,531 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. TD Securities reduced their target price on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Trading Down 0.4 %

Johnson & Johnson stock opened at $157.76 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The business’s fifty day simple moving average is $162.96 and its two-hundred day simple moving average is $155.76. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a market capitalization of $379.83 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the company posted $2.66 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.14%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.